{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-030924","form_type":"8-K","ticker":"NVAX","cik":"0001000694","company_name":"NOVAVAX INC","filed_at":"2026-05-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:31.764979+00:00","generated_at":"2026-05-14T22:26:01.593889+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Novavax Q1 revenue $140M, net loss $9M; Pfizer Matrix-M deal adds $30M upfront","bullets":["Total revenue $140M, down 79% YoY; prior-year included $603M non-cash APA close-out.","Net loss $9M vs net income $519M in Q1 2025; cash $795M, up from $751M.","Pfizer non-exclusive Matrix-M license yielded $30M upfront, potential milestones up to $500M.","Matrix-M partnering expanded: four top-10 pharma companies exploring over 30 fields; new MTAs signed.","FY 2026 guidance reiterated: Non-GAAP combined R&D+SG&A $310-340M; cash position strengthened by $330M credit facility."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-030924","json":"https://secwatch.observer/filing/0001628280-26-030924.json","markdown":"https://secwatch.observer/filing/0001628280-26-030924.md","text":"https://secwatch.observer/filing/0001628280-26-030924.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1000694/000162828026030924/0001628280-26-030924-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1000694/000162828026030924/nvax-20260506.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T22:26:01.593889+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e2d2a33482f37a1df9749ba72910fc01342ca38b","claim":"NOVAVAX INC reported the first quarter ended March 31, 2026 results: revenue Total revenue of $140 million in the first quarter of 2026. Guidance reaffirmed.","evidence_excerpt":"Novavax Reports First Quarter 2026 Financial Results and Operational Highlights • Total revenue of $140 million in the first quarter of 2026","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1000694/000162828026030924/0001628280-26-030924-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2026"},{"label":"Revenue","value":"Total revenue of $140 million in the first quarter of 2026"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}